Skip to Content
MilliporeSigma
  • Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice.

Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice.

Behavioural pharmacology (2015-05-02)
Shigeru Hasebe, Yukio Ago, Saki Nishiyama, Satoshi Oka, Hitoshi Hashimoto, Kazuhiro Takuma, Toshio Matsuda
ABSTRACT

We have recently found that isolation-reared mice show hyperactivity during an encounter with an intruder. However, it is not known whether encounter-induced hyperactivity may model some aspects of psychiatric disorders. The present study examined the pharmacological profile of encounter-induced hyperactivity in isolation-reared mice. Encounter-induced hyperactivity was reduced by acute administration of various antidepressants including the tricyclic antidepressant desipramine (10 mg/kg), the selective serotonin (5-HT) reuptake inhibitors fluvoxamine (10 mg/kg) and paroxetine (10 mg/kg), the 5-HT/noradrenaline reuptake inhibitors venlafaxine (10 mg/kg) and duloxetine (10 mg/kg), the antipsychotic drug risperidone (0.01 mg/kg), the 5-HT2 antagonist ritanserin (1 mg/kg), and the glucocorticoid receptor antagonist RU-43044 (30 mg/kg). The α2 adrenoceptor agonist clonidine (0.03 mg/kg) and the 5-HT4 receptor agonist BIMU8 (30 mg/kg) also reduced encounter-induced hyperactivity. The effect of desipramine was blocked by the α2 adrenoceptor antagonist idazoxan (0.3 mg/kg). The effect of fluvoxamine was blocked by the 5-HT4 receptor antagonist GR125487 (3 mg/kg), but not the 5-HT1A receptor antagonist WAY100635 (1 mg/kg), the 5-HT3 receptor antagonist azasetron (3 mg/kg), or the 5-HT6 receptor antagonist SB399885 (3 mg/kg). The effect of venlafaxine was blocked by the simultaneous administration of idazoxan (0.3 mg/kg) and GR125487 (3 mg/kg), but not by either compound alone. These findings suggest that encounter-induced hyperactivity in isolation-reared mice is a robust model for testing the pharmacological profile of antidepressants, although the range of antidepressants tested is limited and some non-antidepressants are also effective. The present study also shows a key role of α2 and 5-HT4 receptors in the antidepressant effect in this model.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrochloric acid solution, ~6 M in H2O, for amino acid analysis
Supelco
Hydrochloric acid solution, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Hydrochloric acid solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Fluvoxamine maleate, solid
Sigma-Aldrich
Hydrochloric acid, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
Haloperidol, powder
Sigma-Aldrich
Hydrochloric acid solution, 0.5 M
Sigma-Aldrich
Hydrochloric acid solution, 0.2 M
Sigma-Aldrich
Hydrochloric acid solution, 0.02 M
Sigma-Aldrich
Hydrochloric acid solution, 0.05 M
Sigma-Aldrich
Hydrochloric acid, SAJ first grade, 35.0-37.0%
Sigma-Aldrich
Hydrochloric acid solution, 6 M
Sigma-Aldrich
Hydrochloric acid, JIS special grade, 35.0-37.0%
Sigma-Aldrich
Hydrochloric acid solution, 0.01 M
Sigma-Aldrich
Hydrogen chloride – ethanol solution, 0.1 M in ethanol
Sigma-Aldrich
Hydrochloric acid solution, 12 M
Sigma-Aldrich
Hydrochloric acid solution, 2 M
Sigma-Aldrich
Hydrochloric acid solution, 1 M
Sigma-Aldrich
Risperidone, ≥98% (HPLC), powder
Sigma-Aldrich
Hydrogen chloride solution, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
Venlafaxine hydrochloride, ≥98% (HPLC), powder
Supelco
Desipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Hydrochloric acid solution, 32 wt. % in H2O, FCC
Sigma-Aldrich
Hydrogen chloride, ReagentPlus®, ≥99%
Sigma-Aldrich
Prazosin hydrochloride, ≥99.0% (HPLC)
Sigma-Aldrich
Desipramine hydrochloride, ≥98% (TLC), powder